MStranslate logo
Log In
Lost your password?
Lost Password
Back to login
Search
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
Breaking
  • Assessing & Monitoring Cognition in MS
  • Potential Changes to MS Treatment Access in Australia
  • MS Auckland Webinar: AHSCT as a Treatment for MS
  • MS Auckland Webinar: Remyelination Research in MS
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us

Monthly Archives November 24, 2015

video

Determining the Effectiveness of MS Treatments

MStranslate
November 24, 2015
Social Media, Treatments, Uncategorized
A short video summarising the key findings of a recent paper, titled "Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple...

Safety of Gadolinium-based Contrast Agents for MRI

MStranslate
November 16, 2015
Neuroimaging
The U.S. Food and Drug Administration recently issued a safety communication on the use of gadolinium-based contrast agents for Magnetic Resonance Imaging (MRI).  As this has relevance for many people...
Multiple Sclerosis

Living with Multiple Sclerosis: Reflections

MStranslate
November 2, 2015
Community, Videos
Our new video, "Reflections", features a selection of positive, personal insights from members of the multiple sclerosis (MS) community worldwide. The quotes used have been taken from online news articles,...

Recent Posts

  • Assessing & Monitoring Cognition in MS
  • Potential Changes to MS Treatment Access in Australia
  • MS Auckland Webinar: AHSCT as a Treatment for MS
  • MS Auckland Webinar: Remyelination Research in MS
  • FDA Decision On Tolebrutinib

Recent Comments

  • MStranslate on Multiple Sclerosis Research In 2026
  • MStranslate on Multiple Sclerosis Research In 2026
  • K on Multiple Sclerosis Research In 2026
  • Mohammad on Multiple Sclerosis Research In 2026
  • FDA Decision On Tolebrutinib - MStranslate on Multiple Sclerosis in 2025 – Key Developments to Date

Calendar

November 2015
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« Oct   Dec »

Archives

Categories

Posts

  • Assessing & Monitoring Cognition in MS
  • Potential Changes to MS Treatment Access in Australia
  • MS Auckland Webinar: AHSCT as a Treatment for MS
  • MS Auckland Webinar: Remyelination Research in MS
  • FDA Decision On Tolebrutinib

Google+

Get social

Copyright 2014-2018 MStranslate. All Rights Reserved. Contact Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.